

## Data Supplement

**Supplementary Table 1.** Baseline patient demographics and clinical characteristics in DMARD-naïve PALACE 4 patients randomized to apremilast 30 mg BID at baseline, by Week 52 cDAPSA category\*

	REM	LDA	ModDA	HDA
cDAPSA category at Week 52	(n = 17)	(n = 45)	(n = 52)	(n = 24)
	47.1 (10.7)	47.5 (12.6)	48.9 (11.5)	49.8 (10.8)
Age, years	48.0 [27–72]	51.0 [22–69]	51.0 [19–69]	51.5 [25–71]
Women, n (%)	10 (58.8)	21 (46.7)	26 (50.0)	15 (62.5)
	29.4 (6.4)	29.3 (6.8)	29.5 (6.0)	33.6 (5.4)
Body mass index, kg/m <sup>2</sup>	29.4 [17.7–43.8]	28.2 [16.9–54.4]	28.8 [19.6–47.0]	33.7 [23.8–43.8]
	1.5 (2.2)	3.0 (3.9)	4.4 (6.0)	4.6 (6.5)
Duration of PsA, years	0.4 [0.2–7.0]	0.9 [0.2–13.6]	1.8 [0.2–26.5]	1.2 [0.2–21.2]
	16.7 (15.0)	15.8 (13.5)	14.3 (10.9)	18.4 (16.1)
Duration of psoriasis, years	7.0 [0.2–41.9]	13.9 [0.4–47.9]	12.1 [0.2–41.8]	15.3 [0.7–51.8]
	26.1 (15.4)	30.6 (12.4)	41.0 (19.3)	56.2 (24.2)
cDAPSA (0–154)	23.5 [11.0–79.9]	30.0 [11.0–65.4]	37.3 [16.7–108.2]	57.3 [20.8–103.2]
	6.3 (3.4)	6.9 (3.8)	11.7 (9.3)	14.1 (8.8)
SJC (0–66)	6.0 [3–17]	6.0 [2–17]	10.0 [1–48]	12.0 [3–33]
	10.3 (10.5)	13.6 (9.1)	19.0 (10.7)	29.9 (17.6)
TJC (0–68)				

	8.0	11.0	17.0	26.5
	[4–49]	[3–51]	[4–52]	[6–68]
	42.3 (20.8)	51.1 (21.9)	50.5 (20.4)	61.7 (21.0)
PAP (VAS 0–100 mm)	41.0	50.0	50.5	61.0
	[4–76]	[5–88]	[6–97]	[17–100]
	52.5 (15.6)	50.0 (20.0)	52.5 (19.7)	60.7 (21.7)
PtGA (VAS 0–100 mm)	55.0	49.0	52.5	61.5
	[23–74]	[5–88]	[4–99]	[10–96]
	44.4 (13.3)	47.6 (18.0)	53.6 (15.8)	61.7 (17.3)
PhGA (VAS 0–100 mm)	47.0	44.0	54.0	63.5
	[17–68]	[16–84]	[18–86]	[26–86]
	6.6 (3.5)	6.4 (6.0)	6.8 (4.7)	8.4 (5.4)
PASI score (0–72) <sup>†</sup>	5.4	4.7	5.6	8.8
	[2.6–13.2]	[0.8–28.5]	[0.9–20.5]	[1.8–15.4]
	3.4 (1.5)	3.6 (3.0)	3.1 (2.6)	5.1 (3.9)
MASES (0–13) <sup>‡</sup>	3.0	2.0	2.0	3.0
	[2–5]	[1–13]	[1–11]	[1–13]
	2.8 (2.6)	2.6 (4.4)	4.0 (3.0)	4.9 (3.7)
Dactylitis count (0–20) <sup>§</sup>	2.0	1.0	3.0	3.0
	[1–8]	[1–20]	[1–13]	[1–12]
	1.0 (0.6)	1.0 (0.6)	1.1 (0.5)	1.3 (0.5)
HAQ-DI (0–3)	1.1	1.0	1.1	1.3
	[0.0–2.0]	[0.0–1.9]	[0.0–2.4]	[0.1–2.1]
Corticosteroid use, n (%)	2 (11.8)	2 (4.4)	4 (7.7)	2 (8.3)
NSAID use, n (%)	13 (76.5)	34 (75.6)	41 (78.8)	19 (79.2)

\* Values are mean (SD), median [range] unless otherwise indicated. Includes patients randomized at baseline who had cDAPSA components available at Week 52. REM, cDAPSA ≤4; LDA, cDAPSA >4 to ≤13; Mod, cDAPSA >13 to

≤27; HDA, cDAPSA >27. The n represents the number of patients by the Week 52 cDAPSA category and may vary for each parameter due to missing data at baseline. cDAPSA = Clinical Disease Activity Index for Psoriatic Arthritis; HAQ-DI = Health Assessment Questionnaire-Disability Index; HDA = high disease activity; LDA = low disease activity; MASES = Maastricht Ankylosing Spondylitis Enthesitis Score; Mod = moderate disease activity; NSAID = non-steroidal anti-inflammatory drug; PAP = Patient's Assessment of Pain; PASI = Psoriasis Area and Severity Index; PhGA = Physician's Global Assessment of Disease Activity; PsA = psoriatic arthritis; PtGA = Patient's Global Assessment of Disease Activity; REM = remission; SJC = swollen joint count; TJC = tender joint count; VAS = visual analog scale.

† Patients with baseline psoriasis body surface area involvement ≥3%.

‡ Patients with pre-existing enthesitis.

§ Patients with pre-existing dactylitis.

**Supplementary Table 2.** Baseline demographics and disease characteristics in patients with  $\geq 1$  extra-articular manifestation of psoriatic arthritis (skin involvement, enthesitis, and/or dactylitis) treated with apremilast\*

Demographic/disease characteristic	Apremilast (N = 165)
	48.8 (12.5)
Age, years	51.0 [19–74]
Women, n (%)	87 (52.7)
	29.9 (6.5)
Body mass index, kg/m <sup>2</sup>	29.2 [16.9–54.4]
	3.6 (5.0)
Duration of PsA, years	1.3 [0.2–26.5]
	15.5 (13.3)
Duration of psoriasis, years	13.2 [0.2–51.8]
	39.4 (19.7)
cDAPSA (0–154)	34.6 [11.0–108.2]
	10.3 (7.7)
SJC (0–66)	8.0 [1–48]
	18.5 (12.9)
TJC (0–68)	15.0 [3–68]

	52.8 (21.5)
PAP (VAS 0–100 mm)	54.0
	[4–100]
	53.8 (20.1)
PtGA (VAS 0–100 mm)	55.0
	[4–99]
	52.2 (17.6)
PhGA (VAS 0–100 mm)	53.0
	[6–91]
	6.6 (5.1)
PASI score (0–72) <sup>†</sup>	5.1
	[0.7–28.5]
	3.8 (3.0)
MASES (0–13) <sup>‡</sup>	2.0
	[1–13]
	3.5 (3.3)
Dactylitis count (0–20) <sup>§</sup>	2.0
	[1–20]
	1.1 (0.6)
HAQ-DI (0–3)	1.1
	[0.0–2.6]
Corticosteroid use, n (%)	13 (7.9)
NSAID use, n (%)	126 (76.4)

\* Values are mean (SD), median [range] unless otherwise indicated.

<sup>†</sup> In patients with BSA  $\geq$ 3% at baseline.


<sup>‡</sup> In patients with enthesitis at baseline.

<sup>§</sup> In patients with dactylitis at baseline.

cDAPSA = Clinical Disease Activity Index for Psoriatic Arthritis; MASES = Maastricht Ankylosing Spondylitis Enthesitis Score; NSAID = non-steroidal anti-rheumatic drug; PASI = Psoriasis Area and Severity Index; PAP =

Patient's Assessment of Pain; PhGA = Physician's Global Assessment of Disease Activity; PtGA = Patient's Global Assessment of Disease Activity; SJC = swollen joint count; TJC = tender joint count; VAS = visual analog scale.

**Supplementary Figure 1.** Articular disease activity in patients by Week 52 Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) category—(A) SJC and (B) TJC. Data as observed. Includes patients randomized at baseline who had cDAPSA components available at Week 52. HDA = high disease activity; LDA = low disease activity; ModDA = moderate disease activity; REM = remission; SJC = swollen joint count; TJC = tender joint count.



**Supplementary Figure 2.** Extra-articular disease activity in patients by Week 52 Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) category—(A) enthesitis; (B) dactylitis; (C) physical function; and (D) skin. Data as observed. HAQ-DI = Health Assessment Questionnaire-Disability Index; HDA = high disease activity; LDA = low disease activity; MASES = Maastricht Ankylosing Spondylitis Enthesitis Score; ModDA = moderate disease activity; PASI = Psoriasis Area and Severity Index; REM = remission.

